Broadening anticancer spectrum by preprocessing and treatment of T- lymphocytes expressed FcγRI and monoclonal antibodies for refractory cancers

BackgroundChimeric antigen receptor T (CAR-T) cell therapies have achieved remarkable success in the treatment of hematological tumors. However, given the distinct features of solid tumors, particularly heterogeneity, metabolic aggressiveness, and fewer immune cells in tumor microenvironment (TME),...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lei Tang, Qinyi Sun, Mengyuan Li, Xiaoxiao Yu, Jinguo Meng, Yun Zhang, Yuxiao Ma, Aizhong Zeng, Zhuolan Li, Yuanyuan Liu, Xinyu Xu, Wei Guo
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-06-01
coleção:	Frontiers in Immunology
Assuntos:	CAR-T monoclonal antibodies FcγRI ADCC solid tumors
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1400177/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!